<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237639</url>
  </required_header>
  <id_info>
    <org_study_id>20120673</org_study_id>
    <nct_id>NCT01237639</nct_id>
  </id_info>
  <brief_title>Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>TRIST</acronym>
  <official_title>Transfusion of Red Cells in Hematopoietic Stem Cell Transplantation: The TRIST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Blood Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ottawa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saskatchewan Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transfusion of red blood cells (RBCs) is important for the care of patients undergoing stem
      cell transplantation. Stem cell transplants are used to treat blood cancers and bone marrow
      disorders. This involves the use of high doses of chemotherapy and/or radiation to kill
      cancer cells; but this damages the marrow and blood system. Blood stem cells are transplanted
      by infusing into the recipient and blood counts recover over 2-3 weeks. Before bone marrow
      recovery, RBCs are needed to support the patient. Higher hemoglobin in these high risk
      patients may have benefits such as better energy and organ function. However, research in
      other areas of medicine suggests that a higher red cell count may be dangerous. Taken
      together, it is unclear whether having a lower or higher red cell count is better for
      patients having a blood stem cell transplant. The investigators plan to study this by
      randomly assigning patients having a transplant to be transfused with RBCs either at a higher
      or lower hemoglobin level. In this way, the investigators will be able to accurately find out
      if there are any benefits or harms in having a lower or higher red cell count during the
      recovery period after blood stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Males or females aged 18 years or older who are undergoing either an autologous or
           allogeneic HSCT.

        2. The indications for HSCT may include, but not limited to the following diseases :

             1. Acute Leukemia, myeloid, lymphoid or biphenotypic in 1st, 2nd remission or in
                relapse

             2. Chronic Myeloid Leukemia in chronic, accelerated or blast phase

             3. Chronic Lymphocytic Leukemia

             4. Myelodysplastic Syndrome

             5. Myeloproliferative Disorder

             6. Lymphoma

             7. Myeloma

        3. All study patients must provide consent at least 1 day prior to scheduled HSCT and
           provide written informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life (QOL)/Function based on the FACT-BMT scale</measure>
    <time_frame>3 years</time_frame>
    <description>The FACT consists of 5 subscales that measure physical well-being, functional well-being, social/family well-being and emotional well-being. The BMT subscale of the FACT includes additional items specifically designed to test quality of life and symptoms specific to BMT patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant Related Mortality</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Cell Transfusion</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Transfusion</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>100 days</time_frame>
    <description>Grade 3 or 4 by WHO scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Infections</measure>
    <time_frame>100 days</time_frame>
    <description>All grade 4 and 5 infections (according to the CTCAE v.4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Non-relapse Mortality</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Economic Evaluation/Quality of Life</measure>
    <time_frame>100 days</time_frame>
    <description>EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NCI Toxicity Scale</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Restrictive Red blood cell Transfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transfusion Trigger of 70g/L with an aim to maintain Hemoglobin between 80-90g/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liberal Red blood Cell Transfusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transfusion Trigger of 90g/L with an aim to maintain Hemoglobin between 100-110g/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Red blood cell Transfusion</intervention_name>
    <description>Transfusion of Red blood cells to based on daily complete blood count</description>
    <arm_group_label>Restrictive Red blood cell Transfusion</arm_group_label>
    <arm_group_label>Liberal Red blood Cell Transfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients are aged 16-70 undergoing either an autologous or allogeneic HSCT for any
             hematologic malignancy

        Exclusion Criteria:

          -  Pregnant or lactating at the time of enrollment

          -  Already received red cell transfusion after HSCT but prior to enrollment

          -  Unable/unwilling to provide informed consent.

          -  Patients receiving HSCT for non-malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Tay, MD FRCPC MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre, University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatchewan Cancer Centre</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Tay J, Tinmouth A, Fergusson D, Allan D. Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial. Trials. 2011 Sep 21;12:207. doi: 10.1186/1745-6215-12-207.</citation>
    <PMID>21936907</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>November 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red Cells</keyword>
  <keyword>Transfusion</keyword>
  <keyword>Trigger</keyword>
  <keyword>Threshold</keyword>
  <keyword>Hematopoietic Stem cell Transplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

